Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

Table 2

Parasite clearance and fever clearance in number of patients during chloroquine therapy.

Time point	Parasite clearance; (%)	Fever clearance; (%)
At 6 hrs	NA	122 (33.9)
At 12 hrs	35 (9.7)	150 (41.7)
At 18 hrs	NA	159 (44.2)
At 24 hrs	117 (32.5)	173 (48.1)
At 30 hrs	NA	163 (45.3)
At 36 hrs	222 (61.7)	241 (66.9)
At 42 hrs	NA	284 (78.9)
At 48 hrs	281 (78.1)	314 (87.2)
At 54 hrs	NA	325 (90.3)
At 60 hrs	325 (90.3)	345 (95.8)
At 66 hrs	NA	349 (96.9)
At 72 hrs	358 (99.4)	352 (97.8)
At 78 hrs	NA	357 (99.2)
At 84 hrs	NA	358 (99.4)

The data includes all patients who were included to receive chloroquine therapy, NA: not applicable values.